1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

  • October 2014
  • -
  • Global Markets Direct
  • -
  • 36 pages

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014’, provides an overview of the Hormone-Sensitive Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hormone-Sensitive Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone-Sensitive Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hormone-Sensitive Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hormone-Sensitive Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hormone-Sensitive Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hormone-Sensitive Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hormone-Sensitive Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hormone-Sensitive Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hormone-Sensitive Prostate Cancer - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hormone-Sensitive Prostate Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Hormone-Sensitive Prostate Cancer - Overview 7
Pipeline Products for Hormone-Sensitive Prostate Cancer - Comparative Analysis 8
Hormone-Sensitive Prostate Cancer - Therapeutics under Development by Companies 9
Hormone-Sensitive Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 10
Hormone-Sensitive Prostate Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hormone-Sensitive Prostate Cancer - Products under Development by Companies 13
Hormone-Sensitive Prostate Cancer - Products under Investigation by Universities/Institutes 14
Hormone-Sensitive Prostate Cancer - Companies Involved in Therapeutics Development 15
Ipsen S.A. 15
Ultimovacs AS 16
Hormone-Sensitive Prostate Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Peptide Based Therapeutic Cancer Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Vaccine to Target Prostate Specific Antigen for Hormone-Sensitive Prostate Cancer - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
STX-2171 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MVI-118 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Small Molecules to Inhibit AKR1C3 for Oncology - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Hormone-Sensitive Prostate Cancer - Recent Pipeline Updates 31
Hormone-Sensitive Prostate Cancer - Dormant Projects 32
Hormone-Sensitive Prostate Cancer - Discontinued Products 33
Hormone-Sensitive Prostate Cancer - Product Development Milestones 34
Featured News and Press Releases 34
Apr 15, 2014: UK NICE guidance recommends FIRMAGON (degarelix) for the treatment of advanced hormone-dependent prostate cancer only in people with spinal metastases who present with signs or symptoms of impending spinal cord compression 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36

List of Tables

Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014 7
Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Hormone-Sensitive Prostate Cancer - Pipeline by Ipsen S.A., H2 2014 15
Hormone-Sensitive Prostate Cancer - Pipeline by Ultimovacs AS, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Hormone-Sensitive Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 31
Hormone-Sensitive Prostate Cancer - Dormant Projects, H2 2014 32
Hormone-Sensitive Prostate Cancer - Discontinued Products, H2 2014 33

List of Figures

Number of Products under Development for Hormone-Sensitive Prostate Cancer, H2 2014 7
Number of Products under Development for Hormone-Sensitive Prostate Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Target, H2 2014 18
Number of Products by Stage and Top 10 Target, H2 2014 19
Number of Products by Top 10 Mechanism of Action, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 21
Number of Products by Top 10 Route of Administration, H2 2014 22
Number of Products by Stage and Top 10 Route of Administration, H2 2014 23
Number of Products by Top 10 Molecule Type, H2 2014 24
Number of Products by Stage and Top 10 Molecule Type, H2 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

2016 Europe Tumor Marker Testing in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppl

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.